First company awarded market authorisation under new Chinese drug law
The mAb tislelizumab has been granted approval from Chinese authorities,…
The mAb tislelizumab has been granted approval from Chinese authorities, making Boehringer Ingelheim Biopharmaceuticals the first MAH under the new system.